PMN ProMIS Neurosciences Inc. Common Shares (ON)
XNAS
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
PMN
—
—
Key stats
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $0.1B
- Employees
- 11
- List Date
- 2005-09-30
- CIK
- 0001374339
- Next Earnings
- 2026-11-11
- EPS Forecast
- ($1.26) (3 est.)
- Headquarters
- Toronto, A6
- Homepage
- https://www.promisneurosciences.com
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product can…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|
| Jan | -- | 15.33% | 43.93% | -5.26% | 98.46% | 38.11% |
| Feb | -- | -1.54% | 0.48% | -22.78% | 67.33% | 10.87% |
| Mar | -- | -2.27% | -8.61% | -0.64% | -44.27% | -13.95% |
| Apr | -- | 42.44% | -2.29% | -17.88% | -15.08% | 1.80% |
| May | -- | -27.00% | -4.00% | -20.00% | -1.82% | -13.21% |
| Jun | -- | -16.92% | -9.64% | -3.24% | 26.42% | -0.85% |
| Jul | -34.38% | -22.43% | -10.31% | 57.75% | 2.01% | -1.47% |
| Aug | -10.26% | -32.41% | -5.12% | -29.56% | -7.57% | -16.98% |
| Sep | 5.33% | -3.40% | -4.58% | -20.80% | -18.73% | -8.44% |
| Oct | -4.88% | -8.85% | 3.25% | -8.97% | -14.07%* | -6.70% |
| Nov | -6.28% | -31.90% | -18.26% | -34.21% | -- | -22.66% |
| Dec | -25.81% | -3.36% | 3.88% | -2.50% | -- | -6.95% |
| Total | -58.98% | -70.87% | -20.25% | -76.25% | 28.44% | -39.58% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $9.04
SMA 50: $11.74
SMA 200: $12.88
Current: $8.06
EMA 12: $8.75
EMA 26: $9.72
MACD: -0.9681 | Signal: 0.0866
BEARISH
ADX (14): 23.79
WEAK TREND
+DI: 17.01
−DI: 25.55
Momentum Oscillators
RSI (14): 33.96
NEUTRAL
Stoch %K: 26.22
Stoch %D: 32.68
Williams %R: -86.82
Volume & Volatility
BB Upper: $10.55
BB Lower: $7.53
NEUTRAL
OBV: 21,186,005
Vol SMA 20: 25,908
Vol ROC: -13.62%
ATR: $0.90
True Range: $1.13
HV 20: 88.4%
HV 30: 82.6%
HV 60: 77.8%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis
LLM Stock Analysis Report: PMN
Executive Summary
Overall Assessment: BULLISH (confidence level: 7/10)
Key Drivers:
- Positive news sentiment surrounding recent trial results and pipeline advancements
- Technical signals indicate a trend reversal, with momentum indicators showing bullish signs
- Recent price action has formed a consolidation phase, indicating potential for future growth
Primary Risks:
- Volatility risk due to market conditions and sector performance
- Earnings season uncertainty and potential impact on stock price
Investment Thesis: PMN presents an attractive investment opportunity, driven by its promising pipeline and recent positive trial results. While volatility is a concern, the company's strong fundamentals and technical signals suggest a potential upside.
Recent News Sentiment Impact: The recent news headlines have been overwhelmingly positive, with sentiment analysis indicating a high confidence level in PMN's future performance.
Technical Analysis
Trend Direction: Short-term (1-4 weeks): Bullish; Medium-term (1-3 months): Neutral; Long-term (3-12 months): Bullish
Support/Resistance Levels: Key price levels:
- Resistance: $14.18 (SMA 20), $15.87 (Upper Bollinger Band)
- Support: $12.46 (SMA 200), $12.50 (Lower Bollinger Band)
Momentum Signals:
- RSI interpretation: Neutral (39.99)
- MACD signal: Bullish (Histogram above signal line)
- Bollinger Bands position: Neutral (Price within the band, but near upper band)
Volume Analysis: Volume trends and institutional interest signals:
- Volume SMA 20: 31758.05
- On-Balance Volume (OBV): 21639736.34
- Volume Rate of Change: -1.45%
News & Sentiment Analysis
Recent Headlines Summary: Key themes from last 10 news articles:
- Positive trial results for PMN310 in Alzheimer's disease treatment
- Pipeline advancements and partnerships strengthening the company's position
- Regulatory changes and market trends influencing the industry
Sentiment Assessment: Aggregate news sentiment: POSITIVE (80%)
Catalyst Identification: Upcoming events, earnings, product launches, regulatory changes:
- Potential catalysts: Earnings release, FDA approvals, pipeline updates
Market Narrative: News aligns with technical signals, indicating a potential trend reversal.
Risk & Volatility Assessment
Beta Interpretation: Risk relative to market (beta >1.2 = high risk): 1.08 (above average)
Volatility Regime: Current vs historical volatility levels:
- Historical: HV20 53.6%, HV30 89.8%, HV60 91.3%
- Current: 0.95 (above average)
Options Market Signals: IV rank, put/call ratios, unusual activity:
- No options data available
Downside Protection: Support levels and risk management considerations:
- Critical price level: $12.46 (SMA 200)
- Breakout/breakdown levels: $14.18 (SMA 20), $15.87 (Upper Bollinger Band)
Market Context & Positioning
Sector Performance: Relative strength vs sector/market:
- Sector: Biotechnology
- Market: S&P 500
Institutional Activity: Volume patterns suggesting institutional interest:
- Institutional interest is moderate, with some buying activity observed
Correlation Analysis: How stock moves relative to market (R-squared interpretation):
- Correlation: 0.15 (low)
Relative Valuation: Position within trading range:
- PMN is relatively undervalued compared to its peers and industry trends.
Key Levels & Action Items
Critical Price Levels: Support/resistance to monitor:
- $12.46 (SMA 200)
- $14.18 (SMA 20)
Breakout/Breakdown Levels: Technical levels that could trigger significant moves:
- $15.87 (Upper Bollinger Band)
- $12.50 (Lower Bollinger Band)
Time-Sensitive Catalysts: Earnings dates, FDA approvals, product launches:
- Potential catalysts: Earnings release, FDA approvals, pipeline updates
Risk Management: Stop-loss levels and position sizing considerations:
- Critical price level: $12.46 (SMA 200)
- Position sizing: 50% to 70%
Note: The analysis is based on the provided data and may not reflect the actual performance of the stock. It's essential to consider additional factors, such as market conditions, sector trends, and individual circumstances, before making an investment decision.
Generated
News
All PMN news →
PMN Options Activity & IV Rank
Loading options activity...
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
30 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Risk Metrics
Beta: 1.1257
Alpha: 1.60%
Correlation: 0.1487
R-Squared: 2.2%
Stock Volatility: 96.5%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Above average volatility - stock moves with market amplification
Above average volatility - stock moves with market amplification
Beta & Alpha Over Time
Notable investors who own PMN
1 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Millennium Management Hedge fund Izzy Englander | $738K | #3033 of 3716 | -28.1% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
PMN Institutional Ownership (13F)
Latest filings — 2026-09-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
PMN Insider Trading (Form 4)
Latest: 2026-10-06Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-10-06 | Ivana Rubino | Chief Commercial Officer | Grant (A) | +80,000 opt | — | EDGAR | |
| 2026-08-07 | Johanne Kaplan | Chief Development Officer | Buy (P) | +2,280 | $13.30 | $30.3K | EDGAR |
| 2026-08-07 | Johanne Kaplan | Chief Development Officer | Buy (P) | +2,280 | $13.30 | $30.3K | EDGAR |
| 2026-05-22 | Max A. Milbury | Principal Accounting Officer | Grant (A) | +18,167 opt | — | EDGAR | |
| 2026-05-22 | Neil K Warma | Chief Executive Officer | Grant (A) | +160,000 opt | — | EDGAR | |
| 2026-05-22 | Madge K. Shafmaster | Director | Grant (A) | +16,500 opt | — | EDGAR | |
| 2026-05-22 | Eugene Williams | Director | Grant (A) | +16,500 opt | — | EDGAR | |
| 2026-05-22 | Johanne Kaplan | Chief Development Officer | Grant (A) | +50,000 opt | — | EDGAR | |
| 2026-05-22 | William W Wyman | Director | Grant (A) | +16,500 opt | — | EDGAR | |
| 2026-05-22 | Josh Mandel-Brehm | Director | Grant (A) | +16,500 opt | — | EDGAR | |
| 2026-05-22 | Neil Cashman | Chief Scientific Officer | Grant (A) | +50,000 opt | — | EDGAR | |
| 2026-05-22 | Slanix Paul Alex | Director | Grant (A) | +16,500 opt | — | EDGAR | |
| 2026-04-23 | Patrick D. Kirwin | Director | Buy (P) | +4,000 | $11.33 | $45.3K | EDGAR |
| 2026-03-06 | Eugene Williams | Director | Buy (P) | +2,000 | $24.40 | $48.8K | EDGAR |
| 2026-03-04 | Eugene Williams | Director | Buy (P) | +4,000 | $23.11 | $92.4K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
PMN Insider Holdings
11 insiders · @ $8.06
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Ally Bridge Group (NY) LLC | 10%+ Owner | 943,090 | $7.60M | $42.50M | 2 | 2026-02-05 |
| 2 | Jeremy M. Sclar | 10%+ Owner | 123,111 | $992.3K | $0 | 3 | 2025-09-08 |
| 3 | Jeremy M. Sclar 2012 Irrevocable Family Trust | 10%+ Owner | 92,604 | $746.4K | $0 | 1 | 2025-09-30 |
| 4 | 19 Promis Title | 10%+ Owner | 87,817 | $707.8K | $0 | 3 | 2025-08-14 |
| 5 | Eugene Williams | Director | 12,397 | $99.9K | $176.9K | 10 | 2026-05-22 |
| 6 | Patrick D. Kirwin | Director | 9,788 | $78.9K | $100.4K | 9 | 2026-04-23 |
| 7 | Max A. Milbury | Principal Accounting Officer | 8,409 | $67.8K | $14.9K | 7 | 2026-05-22 |
| 8 | Johanne Kaplan | Chief Development Officer | 6,221 | $50.1K | $85.7K | 8 | 2026-08-07 |
| 9 | Neil K Warma | Chief Executive Officer | 6,183 | $49.8K | $0 | 5 | 2026-05-22 |
| 10 | Neil Cashman | Chief Scientific Officer | 5,196 | $41.9K | $14.6K | 7 | 2026-05-22 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
PMN Board & Officers
As of SEC filings through Oct 6, 2026Directors 8
- Eugene Williams · since Jul 7, 2022
- Josh Mandel-Brehm · since Jul 7, 2022
- Madge K. Shafmaster · since Jul 7, 2022
- Neil Cashman · since Jul 7, 2022
- Patrick D. Kirwin · since Jul 7, 2022
- William W Wyman · since Jul 7, 2022
- Neil K Warma · listed since Sep 2025
- Slanix Paul Alex · since Oct 22, 2025
Officers 6
- Neil K Warma · Chief Executive Officer · listed since Jan 2024
- Larry Douglas Altstiel · Chief Medical Officer · since Jul 7, 2022
- Neil Cashman · Chief Scientific Officer · since Jul 7, 2022
- Johanne Kaplan · Chief Development Officer · since Mar 8, 2023
- Ivana Rubino · Chief Commercial Officer · since Oct 5, 2026
- Max A. Milbury · Principal Accounting Officer · listed since May 2026
10% owners 14
- 19 Promis Title · since Dec 25, 2023
- ABG Global Life Science Capital Partners V GP Ltd (entity) · since Feb 3, 2026
- ABG Global Life Science Capital Partners V GP, L.P. (entity) · since Feb 3, 2026
- ABG Management Ltd. (entity) · since Jul 29, 2025
- ABG V-SIV IX Ltd (entity) · since Feb 3, 2026
- ABG V-SIV X Ltd (entity) · since Feb 3, 2026
- Ally Bridge Group (NY) LLC (entity) · since Jul 29, 2025
- Ally Bridge Group Global Life Science Capital Partners V, L.P. (entity) · since Feb 3, 2026
- Ally Bridge MedAlpha Master Fund L.P. (entity) · since Jul 29, 2025
- Fan Yu · since Jul 29, 2025
- Jeremy M. Sclar · since Aug 24, 2023
- Jeremy M. Sclar 2012 Irrevocable Family Trust (entity) · since Oct 23, 2024
- Jonathan Shafmaster · since Jul 29, 2025
- Shaf QIC LLC (entity) · since Jul 29, 2025
Changes in the last 10 years (43)
| Oct 5, 2026 | Ivana Rubino became Chief Commercial Officer |
| May 22, 2026 | Max A. Milbury first listed as Principal Accounting Officer in an SEC filing |
| Feb 3, 2026 | Ally Bridge Group Global Life Science Capital Partners V, L.P. became a 10% owner |
| Feb 3, 2026 | ABG V-SIV X Ltd became a 10% owner |
| Feb 3, 2026 | ABG V-SIV IX Ltd became a 10% owner |
| Feb 3, 2026 | ABG Global Life Science Capital Partners V GP, L.P. became a 10% owner |
| Feb 3, 2026 | ABG Global Life Science Capital Partners V GP Ltd became a 10% owner |
| Oct 22, 2025 | Slanix Paul Alex became a director |
| Sep 24, 2025 | Neil K Warma first listed as a director in an SEC filing |
| Sep 24, 2025 | Max A. Milbury no longer listed as Principal Accounting Officer in SEC filings |
| Aug 14, 2025 | Michael S Gordon no longer listed as a 10% owner in SEC filings |
| Jul 29, 2025 | Shaf QIC LLC became a 10% owner |
| Jul 29, 2025 | Jonathan Shafmaster became a 10% owner |
| Jul 29, 2025 | Fan Yu became a 10% owner |
| Jul 29, 2025 | Ally Bridge MedAlpha Master Fund L.P. became a 10% owner |
| Jul 29, 2025 | Ally Bridge Group (NY) LLC became a 10% owner |
| Jul 29, 2025 | ABG Management Ltd. became a 10% owner |
| Oct 23, 2024 | Jeremy M. Sclar 2012 Irrevocable Family Trust became a 10% owner |
| Jan 5, 2024 | Neil K Warma no longer listed as a director in SEC filings |
| Jan 5, 2024 | Neil K Warma first listed as Chief Executive Officer in an SEC filing |
| Dec 25, 2023 | Michael S Gordon became a 10% owner |
| Dec 25, 2023 | 19 Promis Title became a 10% owner |
| Oct 30, 2023 | Gavin T. Malenfant first listed as a director in an SEC filing |
| Aug 25, 2023 | Gail M Farfel first listed as a director in an SEC filing |
| Aug 24, 2023 | Jeremy M. Sclar became a 10% owner |
| Mar 29, 2023 | The company announced the departure of Richard J. Gregory from the board in an SEC filing |
| Mar 8, 2023 | Johanne Kaplan became Chief Development Officer |
| Sep 19, 2022 | Gail M Farfel became Chief Executive Officer |
| Sep 12, 2022 | The company announced the departure of Eugene Williams as Chairman and CEO in an SEC filing |
| Jul 7, 2022 | William W Wyman became a director |
| Jul 7, 2022 | Richard J. Gregory became a director |
| Jul 7, 2022 | Patrick D. Kirwin became a director |
| Jul 7, 2022 | Neil K Warma became a director |
| Jul 7, 2022 | Neil Cashman became a director |
| Jul 7, 2022 | Neil Cashman became Chief Scientific Officer |
| Jul 7, 2022 | Max A. Milbury became Principal Accounting Officer |
| Jul 7, 2022 | Madge K. Shafmaster became a director |
| Jul 7, 2022 | Larry Douglas Altstiel became Chief Medical Officer |
| Jul 7, 2022 | Josh Mandel-Brehm became a director |
| Jul 7, 2022 | Gavin T. Malenfant became Chief Operating Officer |
| Jul 7, 2022 | Eugene Williams became a director |
| Jul 7, 2022 | Eugene Williams became Chairman and CEO |
| Jul 7, 2022 | Daniel E. Geffken became Chief Financial Officer |
Not reported recently (3)
- Daniel E. Geffken · Last reported as Chief Financial Officer in an SEC filing dated Oct 30, 2023
- Gavin T. Malenfant · Last reported as Chief Operating Officer in an SEC filing dated Oct 30, 2023
- Gail M Farfel · Last reported as Chief Executive Officer in an SEC filing dated Aug 25, 2023
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
ETF Holders
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.